started · updated
Argenx to acquire Unnatural Products for up to $1.15 billion
Argenx has reached an agreement to fully acquire the American biotechnology company Unnatural Products (UNP) for a total potential value of $1.15 billion. The transaction includes an immediate cash payment of $550 million, with an additional $595 million in contingent payments tied to the achievement of specific regulatory and development milestones.
The acquisition aims to integrate UNP’s specialized macrocyclic peptide discovery platform into Argenx’s existing immunological research. This technology is expected to complement Argenx’s antibody engineering capabilities by enabling the development of long-acting treatments and oral medications that can reach intracellular targets.
UNP will continue its operations from its current site in Santa Cruz, serving as a dedicated discovery hub for Argenx. The deal follows a two-year collaboration between the two companies and a previous investment by Argenx in UNP’s Series B funding round. The transaction is expected to close by the end of the year.
Entities
Cameron Pye · Karen Massey · Santa Cruz · Unnatural Products · argenx